Trump Executive Order Accelerates Psychedelic Research, Signaling Shift in Drug Policy

President Donald Trump has signed an executive order designed to accelerate the research and clinical application of psychedelic substances, including psilocybin, MDMA, and ibogaine. The directive focuses on expanding 'Right to Try' access for patients with severe mental health conditions and streamlining FDA-led clinical trials to legitimize an industry that has historically operated underground. This policy shift arrives as federal efforts to reschedule cannabis have largely stalled within the Drug Enforcement Administration (DEA). Legal experts suggest that the 'medical-first' framework adopted for psychedelics—prioritizing clinical protocols and patient outcomes—could serve as a strategic model for advocates seeking to move cannabis from Schedule I to Schedule III. Equity markets responded positively to the news, with psychedelic-focused drug developers seeing significant gains. AtaiBeckley shares rose approximately 25% on Monday, while other firms, including Compass Pathways, Definium Therapeutics, and Cybin, also recorded price increases. The order specifically includes ibogaine, a compound noted for its potential in treating addiction and PTSD but flagged by the National Institute on Drug Abuse for cardiac risks. Industry leaders emphasize that while the order provides high-level legitimacy, long-term success depends on rigorous scientific execution and safety standards rather than market hype.